Show news: from last 30 days (default), 60 days, 90 days, last visit or all

SMC accepts Epistatus 10mg oromucosal solution

17th November 2017

The Scottish Medicines Consortium (SMC) has accepted the Epistatus® brand of midazolam 10mg oromucosal solution for buccal administration for the treatment of prolonged, acute seizures in children and adolescents aged 10 to <18 years.

Note. This product was authorized earlier in 2017 (see our news item) Epistatus® oromucosal solution is 10mg/mL; this is double the concentration of the other authorized formulation of midazolam oromucosal solution (Buccolam®) in the UK, which is 5mg/mL and available as 2.5mg, 5mg, 7.5mg and 10mg prefilled oral syringes.

click here to view